Carregant...

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure

Lowering IOP is the most readily modifiable risk factor to delay the development and progression of glaucoma (POAG). The fixed combination of brimonidine tartrate 0.2% and timolol maleate 0.5% (FCBT) combines a highly selective α2-adrenergic agonist (brimonidine) with a non-selective β-blocker (timo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lee, Anne J, McCluskey, Peter
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2008
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2694019/
https://ncbi.nlm.nih.gov/pubmed/19668752
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!